{
  "objCls" : "Guideline",
  "@id" : "https://www.pharmgkb.org/data/guideline/PA166104955",
  "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
  "id" : "PA166104955",
  "name" : "Dutch Pharmacogenetics Working Group Guideline for hormonal contraceptives for systemic use and F5",
  "relatedDrugs" : [ {
    "objCls" : "Drug",
    "@id" : "https://www.pharmgkb.org/data/drug/PA452637",
    "@context" : "https://www.pharmgkb.org/jsonld/drug.jsonld",
    "id" : "PA452637",
    "name" : "hormonal contraceptives for systemic use"
  } ],
  "relatedGenes" : [ {
    "objCls" : "Gene",
    "@id" : "https://www.pharmgkb.org/data/gene/PA159",
    "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
    "id" : "PA159",
    "symbol" : "F5",
    "name" : "coagulation factor V (proaccelerin, labile factor)"
  } ],
  "source" : "DPWG",
  "summaryHtml" : "<p>In individuals who carry the Factor V Leiden allele and have a family history of thrombotic events, estrogen-containing oral contraceptives should be avoided and alternative forms of contraception used.</p>",
  "textHtml" : "<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for hormonal contraceptives for systemic use based on Factor V Leiden (FVL, or F5) genotype [Article:<a href=\"/pmid/21412232\">21412232</a>].  They suggest that in individuals who carry the Factor V Leiden allele and have a family history of thrombotic events, estrogen-containing oral contraceptives should be avoided and alternative forms of contraception used. </p><table class=\"table table-striped table-condensed table-hover table-bordered\"><tr><th> Phenotype (Genotype) </th><th> Therapeutic Dose Recommendation </th><th> Level of Evidence </th><th> Clinical Relevance </th></tr><tr><td> F5 homozygous <a href=\"/rsid/rs6025\">rs6025</a> TT </td><td> Positive (family) history of thrombotic events: avoid estrogen-containing oral contraceptives and select alternative (e.g., copper intrauterine device, progestin-only contraceptive). Negative (family) history of thrombotic events: avoid additional risk factors (e.g., obesity, smoking). </td><td> Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. </td><td>Clinical effect (S): long-standing discomfort (&gt; 168 hr), permanent symptom or invalidating injury e.g. failure of prophylaxis of atrial fibrillation; venous thromboembolism; decreased effect of clopidogrel on inhibition of platelet aggregation; ADE resulting from increased bioavailability of phenytoin; INR &gt; 6.0; neutropenia 0.5-1.0x10 <sup>9</sup>/l; leucopenia 1.0-2.0x10 <sup>9</sup>/l; thrombocytopenia 25-50x10 <sup>9</sup>/l; severe diarrhea</td></tr><tr><td> F5 heterozygous <a href=\"/rsid/rs6025\">rs6025</a> CT</td><td> Positive (family) history of thrombotic events: avoid estrogen-containing oral contraceptives and select alternative (e.g., copper intrauterine device, progestin-only contraceptive). Negative (family) history of thrombotic events: avoid additional risk factors (e.g., obesity, smoking). </td><td> Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. </td><td> Clinical effect (S): long-standing discomfort (&gt; 168 hr), permanent symptom or invalidating injury e.g. failure of prophylaxis of atrial fibrillation; venous thromboembolism; decreased effect of clopidogrel on inhibition of platelet aggregation; ADE resulting from increased bioavailability of phenytoin; INR &gt; 6.0; neutropenia 0.5-1.0x10 <sup>9</sup>/l; leucopenia 1.0-2.0x10 <sup>9</sup>/l; thrombocytopenia 25-50x10 <sup>9</sup>/l; severe diarrhea</td></tr></table><ul><li>*See <a href=\"http://www.pharmgkb.org/home/dutch_pharmacogenetics_working_group.jsp\">Methods</a> or <a href=\"http://www.pharmgkb.org/pmid/18253145\">PMID: 18253145</a> for definition of \"good\" and \"moderate\" quality.</li><li>S: statistically significant difference.</li></ul>"
}